STADA Arzneimittel — Q1 2025 Earnings Presentation
30 slides from STADA Arzneimittel's earnings presentation, Jun 3, 2025
Slide 1: STADA Q1 2025 Investor Call
Caring for People’s Health STADA Q1 2025 Investor Call 3 June 2025
Slide 2: Today's presenters
Privileged and Confidential Today’s presenters 30y 20y 20y experience experience experience Peter Goldschmidt Boris Döbler Ingo Schachel Chief Executive Officer Chief Financial Officer Head of Investor Relations Joined in 2018 Joined in 2019 Joined in 2024 PREVIOUS EXPERIENCE PREVIOUS EXPERIENCE PRE
Slide 3: Q1 2025 Highlights
Q1 2025 Highlights Peter Goldschmidt Chief Executive Officer
Slide 4: STADA Q1 2025: Continuing to outgrow in revenues and profit
Q1 2025 Update Summary Privileged and Confidential STADA Q1 2025: Continuing to outgrow in revenues and profit Key highlights in Q1 2025: A record quarter for STADA 1 Growth of +4% in Revenues and +5% Adj. cc EBITDA1 growth2: Adj. cc EBITDA at all-time-high of €245m 2 High resilience with no impact
Slide 5: STADA with continuous growth in Q1, on track for another strong year in 2025
Q1 2025 Update Revenues Privileged and Confidential STADA with continuous growth in Q1, on track for another strong year in 2025 – with high resilience in a turbulent external environment Adj. cc Revenues1,3 (€m) Adj. cc EBITDA2,3 (€m) Growth (%) Growth (%) +4% 1,081 +5% 245 • Resilient revenue grow
Slide 6: Consumer Healthcare: Topline overall flat due to declining seasonal sell-in
Q1 2025 Update Consumer Healthcare Privileged and Confidential Consumer Healthcare: Topline overall flat due to declining seasonal sell-in, while non- seasonal products with MSD1 growth Adj. cc Revenues (€m)2 Growth (%) -0.7% • High PY-base in Q1 20244 - impacted by strong sell-in of 422 419 seasona
Slide 7: Generics: Strong growth outside of Germany based on continued launch successes
Q1 2025 Update Generics Privileged and Confidential Generics: Strong growth outside of Germany based on continued launch successes Adj. cc Revenues (€m)1 Growth (%) +1% • Revenues up +1% against high PY-base which 418 423 included positive one-time-effects in Germany (supply phasing, rebate accrual
Slide 8: Specialty: Very strong growth based on biosimilars and innovative medicines
Q1 2025 Update Specialty Privileged and Confidential Specialty: Very strong growth based on biosimilars, esp. Ustekinumab, and innovative medicines Adj. cc Revenues (€m)1 Growth (%) • Strong revenue contribution of launches e.g. Ustekinumab, Nilotinib +22% 239 196 • Broad-based growth of in-market b
Slide 9: Financial Review Q1 2025
Financial Review Q1 2025 Boris Döbler Chief Financial Officer
Slide 10: STADA Group: consistent growth, healthy P&L-shape and record quarterly Adj. cc EBITDA
Q1 2025 Update STADA Group Privileged and Confidential STADA in Q1 with consistent growth, healthy P&L-shape and a record quarterly Adj. cc EBITDA Q1 Revenues and Adj. cc EBITDA (€m) Q1'25 %-D vs PY Revenue growth of +4%1 with: Revenues 1,081 +4% • Growth excl. seasonal products and one-time effects
Slide 11: On track for 2025 Guidance on Adj. cc EBITDA
Q1 2025 Update Guidance 2025 Privileged and Confidential On track for 2025 Guidance on Adj. cc EBITDA despite softer C&C revenues, demonstrating resilience of STADA’s three segment model Guidance: € or growth rate percentage ranges 2024 Results: KPIs: 2025 Forecast Comment on range of outcome: Reven
Slide 12: Adj. cc EBITDA-evolution throughout the year: High H1 comparator in 2024
Q1 2025 Update Quarterly Progression Privileged and Confidential Adj. cc EBITDA-evolution throughout the year: High H1 comparator in 2024 Adj. cc EBITDA H1 vs H2 – actual results 20241 Reminder: Half-yearly EBITDA-pattern 2024 52% 48% • H1 2024 unusually high based on strong seasonal sell-in and fav
Slide 13: Cash generative business model – Q1 with M&A proceeds
Q1 2025 Update Cash conversion Privileged and Confidential Cash generative business model – Q1 with M&A proceeds to fund growth investments Core Free Cash Flow1 (€m) FY’24 Q1’25 • Core Free Cash Flow exceeding average run-rate in Adj. cc EBITDA 100% 886 100% 245 FY 2024 (€197m vs. ~€142m) Taxes2 -12
Slide 14: STADA's mid-term guidance
Q1 2025 Update Mid-term Guidance Privileged and Confidential STADA’s mid-term guidance: Confident to deliver mid to high single digit topline and margin accretive bottom-line growth Guidance: € or growth rate percentage ranges 2025 Forecast 2024 Results KPIs: Mid-term Guidance (Q1-update) Revenues €
Slide 15: Capital allocation framework in case of a public market listing
Q1 2025 Update Capital allocation Privileged and Confidential Capital allocation framework in case of a public market listing Organic growth investment Proactive management of maturities • Opex to support growth – under-proportionate to • Successful €1.3bn refinancing of Aug-2026 debt Revenues growt
Slide 16: Key Takeaways from Q1 financial update
Q1 2025 Update Summary Privileged and Confidential Key Takeaways from Q1 financial update 1 Strong growth – revenue growth ahead of most peers and Adj. cc EBITDA margin expansion also in Q1 2025 2 Strong resilience – attractive geographic footprint and segment-exposure result in very limited exposur
Slide 17: Closing Remark
Closing Remark Peter Goldschmidt Chief Executive Officer
Slide 18: We continue to deliver on our vision based on our clear strategic framework
Q1 2025 Update Strategic Priorities Privileged and Confidential We continue to deliver on our vision based on our clear strategic framework and culture Purpose “Caring for people’s health as a trusted partner” “To be the partner of choice in Consumer Health, Generics and Vision Specialty continuousl
Slide 19: Entering 2025 with strong momentum along our five strategic priorities
Q1 2025 Update Strategic Priorities Privileged and Confidential Entering 2025 with strong momentum along our five strategic priorities Strong Portfolio Low-cost operating Efficient and reliable Growth marketing and sales acceleration via model supply chain culture capabilities launches, BD&L and M&A
Slide 20: Key Takeaways
Q1 2025 Update Summary Privileged and Confidential Key Takeaways 1 STADA with its strong growth culture has a proven track record of outperforming its relevant markets organically across all three segments 2 Symbiotic business across Consumer Healthcare, Generics and Specialty with leading market po
Slide 21: Appendix: Investment Highlights
Appendix: Investment Highlights
Slide 22: STADA – a distinctive investment case in Healthcare
STADA – a distinctive investment case in Healthcare Peter Goldschmidt Chief Executive Officer
Slide 23: A leading supplier of healthcare products across Self-Care, Primary Care and Specialty Care
Privileged and Confidential A leading supplier of healthcare products across Self-Care (Consumer Healthcare), Primary Care (Generics) and Specialty Care (Specialty), fully integrated across global product development, procurement and manufacturing, and commercialization
Slide 24: STADA – A leading supplier of Healthcare products
Investment highlights Who We Are Privileged and Confidential STADA – A leading supplier of Healthcare 1 products Key financials 2024 Revenues by segment2 Revenues by product2,3,4 Revenues by country2,3,5 Consumer Uzpruvo® Kinpeygo® Specialty Corpos® €4.1bn Versatis® Healthcare Movymia® Nizoral® Rest
Slide 25: Since 2017, significant transformation of a ~130 year heritage company
Investment highlights Where we come from Privileged and Confidential Since 2017, significant transformation of a ~130 year heritage company into a leading supplier of Healthcare1 products Revenues (€bn) Adj. EBITDA (€bn) 6 1.5 CAGR CAGR 1.3 +12% +17% 5 4.1 3.7 1.1 4 3.3 0.9 2.9 0.9 0.8 3 0.7 0.5 0.7
Slide 26: We continue to deliver on our vision based on our clear strategic framework
Investment highlights How we operate Privileged and Confidential We continue to deliver on our vision based on our clear strategic framework and culture Purpose “Caring for people’s health as a trusted partner” “To be the partner of choice in Consumer Health, Generics and Vision Specialty continuous
Slide 27: Focused on large, growing and mostly non-cyclical European Healthcare markets
Investment highlights Markets Privileged and Confidential Focused on large, growing and mostly non-cyclical European Healthcare markets Consumer Healthcare Market Generics Market Specialty Market European Consumer Healthcare market, EUR bn gross European Generics market, EUR bn gross sales European
Slide 28: Consistently outperformed relevant European markets driven by strong organic growth
Investment highlights Markets Privileged and Confidential Consistently outperformed relevant European markets driven by strong organic growth Consumer Healthcare (38%1) Generics (41%1) Specialty (21% 1) The fastest-growing major Consumer Health- A leading Generics player Attractive portfolio of Bios
Slide 29: Three distinct strategies to differentiate STADA in each segment
Investment highlights Segments Privileged and Confidential Three distinct strategies to differentiate STADA in each segment Consumer Healthcare Generics Specialty • Driving portfolio of Local Hero brands1 • Deliberate geographic footprint (e.g. no • Build and grow portfolio with complex, across OTC
Slide 30: STADA – investment highlights
Privileged and Confidential Focused on large, mostly non-cyclical markets growing mid 1 single to low double digit Track-record of outperforming relevant markets1 with leading 2 positioning and attractive risk profile Differentiated strategy for Consumer Healthcare, Generics and Specialty – 3 with s